BioPharmSignal logoBioPharmSignal

Biotech News

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026

Seer, Inc (SEER)Seer, IncPartnership

Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screening REDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for

Related news

SEERSeer, Inc2026-04-09 12:00 EST

Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples

SEERSeer, Inc2026-06-22 11:00 EST

Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening

View all latest news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

SEERSeer, Inc2026-08-11 20:05 EST

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

SEERSeer, Inc2026-08-03 20:15 EST

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

SEERSeer, Inc2026-08-03 20:05 EST

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

SEERSeer, Inc2026-07-30 21:30 EST

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

SEERSeer, Inc2026-07-28 21:40 EST

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

Stock data

Close
2.03 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States